

# Look What is Coming In New Vaccines for Covid

The alleged or so-called novel coronavirus disease 2019 (COVID-19) is still rampant all over the world, causing incalculable losses to the world. Major pharmaceutical organizations around the globe are focusing on vaccine research and drug development to prevent further damage caused by the pandemic. The messenger RNA (mRNA) technology has got ample attention after the success of the two very effective mRNA vaccines during the recent pandemic of COVID-19. mRNA vaccine has been promoted to the core stage of pharmaceutical industry, and the rapid development of mRNA technology has exceeded expectations like never imagined.

Beyond COVID-19, the mRNA vaccine has been tested for various infectious diseases and undergoing clinical trials. Due to the ability of constant mutation, the viral infections demand abrupt responses and immediate production, and therefore mRNA-based technology offers best answers to sudden outbreaks. The need for mRNA-based vaccine became more obvious due to the recent emergence of new Omicron variant. In this review, we summarized the unique properties of mRNA-based vaccines for infectious diseases, delivery technologies, discussed current challenges, and highlighted the prospects of this promising technology in the future. We also discussed various clinical studies as well preclinical studies conducted on mRNA therapeutics for diverse infectious diseases.


The government's NIH library known as PubMed Central site reveals that more than a hundred new vaccines are in the works for Covid-19 and its delivery. What they do not tell you is that the Covid-19 was a patented product in 2013, and 2015, and again in 2017. But it has been revealed by Dr. David L. Martin is that the U.S. has funded the "bioweapon" with taxpayer dollars going back to the 1990s. Actually from a previous statement by Dr. David L. Martin made on another interview, there are over 70 patents on the Covid-19 vaccine, between 1998 and 2019. Remember, it was Dr. Anthony Fauci of the NIAID who said Covid was a "rogue novel virus", or never seen before. Dr. Fauci is the front man for peddling the bovine excrement to frighten you!

David L. Martin was interviewed by Seth of Man In America web page back on 12/21/21. It would be worth your time to listen to a re-run of that program. You can still view it at the link just below:

[Why Does Trump Keep Promoting the Vaccine? - Gab TV](https://sage.gab.com/channel/trump_won_2020_twice/...)  
[https://sage.gab.com/channel/trump\\_won\\_2020\\_twice/...](https://sage.gab.com/channel/trump_won_2020_twice/...)

In that hour and five minutes video you learn how our own government funded the weaponization of the virus SARSCov2. It was under enhancement for more than twenty years. Dr. Martin believes Donald J. Trump was provided false advice.

Well, get a load of what PubMed Central has coming in the months and years just ahead for all you vaccine lovers. When the government bought and paid for the vaxxes the Big Pharma had ready to roll out was an invitation to entrepreneurs wanting to make it big in the vaccine business. It is a billionaire's dream, or a budding scientist dream. PubMed Central is the NIH library of research papers dealing with all kinds of research. Below is a list of well over a hundred research papers listed for those scientists from all over the world working on the next vaccine to scare the public into taking the next time someone has discovered a "rogue novel virus". These vaccines are usually created and patented at the time of their creation as a "bioweapon" that can be released upon an unsuspecting population somewhere in the world or community that can be fear-mongered. A lot more follows the listing of research work linked to CRISPR-Cas9.



**Keywords:** messenger RNA (mRNA) vaccine, lipid-nanoparticle, infectious disease, drug delivery, coronavirus disease 2019 (COVID-19), virus

[Go to:](#)

#### Acknowledgements

This work was supported by the Natural Science Foundation of Guangdong Province (No. 2019A1515010776), the Beijing-Tianjin-Hebei Basic Research Cooperation Project (No. 19JCZDJC64100), the National Key Research and Development Program of China (Nos. 2021YFE0106900, 2021YFA1201002, and 2021YFC2302402), the National Natural Science Foundation of China (Nos. 31871003 and 3217100573), and the Beijing Nova Program from Beijing Municipal Science & Technology Commission (No. Z201100006820005). The authors thank Biological & Medical Engineering Core Facilities (Beijing Institute of Technology) for providing advanced equipment.

[Go to:](#)

#### Contributor Information

Abid Hussain, Email: [nc.ude.tib@hprdiba](mailto:nc.ude.tib@hprdiba).

Yuanyu Huang, Email: [nc.ude.tib@gnauhyy](mailto:nc.ude.tib@gnauhyy).

[Go to:](#)

#### References

[1] Richner J M, Himansu S, Dowd K A, Butler S L, Salazar V, Fox J M, Julander J G, Tang W W, Shresta S, Pierson T C, et al. Modified mRNA vaccines protect against Zika virus infection. *Cell*. 2017;168:1114–1125.e10. doi: 10.1016/j.cell.2017.02.017. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[2] Wolff J A, Malone R W, Williams P, Chong W, Acsadi G, Jani A, Felgner P L. Direct gene transfer into mouse muscle *in vivo*. *Science*. 1990;247:1465–1468. doi: 10.1126/science.1690918. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[3] Pardi N, Hogan M J, Porter F W, Weissman D. mRNA vaccines—A new era in vaccinology. *Nat. Rev. Drug Discov*. 2018;17:261–279. doi: 10.1038/nrd.2017.243. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[4] Weng Y H, Li C H, Yang T R, Hu B, Zhang M J, Guo S, Xiao H H, Liang X J, Huang Y Y. The challenge and prospect of mRNA therapeutics landscape. *Biotechnol. Adv*. 2020;40:107534. doi: 10.1016/j.biotechadv.2020.107534. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[5] Wykes M, Pombo A, Jenkins C, MacPherson G G. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. *J. Immunol*. 1998;161:1313–1319. [[PubMed](#)] [[Google Scholar](#)]

[6] Rybakova Y, Kowalski P S, Huang Y X, Gonzalez J T, Heartlein M W, DeRosa F, Delcassian D, Anderson D G. mRNA delivery for therapeutic anti-HER2 antibody expression *in vivo*. *Mol. Ther*. 2019;27:1415–1423.

doi: 10.1016/j.ymthe.2019.05.012. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[7] Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L M, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responses. *Nature*. 2020;586:594–599. doi: 10.1038/s41586-020-2814-7. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[8] Corbett K S, Edwards D K, Leist S R, Abiona O M, Boyoglu-Barnum S, Gillespie R A, Himansu S, Schäfer A, Ziwawo C T, DiPiazza A T, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature*. 2020;586:567–571. doi: 10.1038/s41586-020-2622-0. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[9] Shin M D, Shukla S, Chung Y H, Beiss V, Chan S K, Ortega-Rivera O A, Wirth D M, Chen A, Sack M, Pokorski J K, et al. COVID-19 vaccine development and a potential nanomaterial path forward. *Nat. Nanotechnol.* 2020;15:646–655. doi: 10.1038/s41565-020-0737-y. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[10] Ding J X, Xiao H H, Chen X S. Advanced biosafety materials for prevention and theranostics of biosafety issues. *Biosaf. Health.* 2022;4:59–60. doi: 10.1016/j.bsheat.2022.03.011. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[11] Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—Developing a new class of drugs. *Nat. Rev. Drug Discov.* 2014;13:759–780. doi: 10.1038/nrd4278. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[12] Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. *Mol. Cancer.* 2021;20:41. doi: 10.1186/s12943-021-01335-5. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[13] Schlake T, Thess A, Fotin-Mleczek M, Kallen K J. Developing mRNA-vaccine technologies. *RNA Biol.* 2012;9:1319–1330. doi: 10.4161/rna.22269. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[14] Karikó K. *In vitro*-transcribed mRNA therapeutics: Out of the shadows and into the spotlight. *Mol. Ther.* 2019;27:691–692. doi: 10.1016/j.ymthe.2019.03.009. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[15] Kristie B, Fiona V D B, Patrick A, et al. Self-amplifying RNA vaccines for infectious diseases. *Nature Gene Therapy.* 2021;28:117–129. doi: 10.1038/s41434-020-00204-y. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

- [16] Anna K B, Shell I, Andrew J G. An update on self-amplifying mRNA vaccine development. *Vaccines (Basel)* 2021;9:97. doi: 10.3390/vaccines9020097. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [17] Vogel A B, Lambert L, Kinnear E, Busse D, Erbar S, Reuter K C, Wicke L, Perkovic M, Beissert T, Haas H, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. *Mol. Ther.* 2018;26:446–455. doi: 10.1016/j.ymthe.2017.11.017. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [18] Richner J M, Jagger B W, Shan C, Fontes C R, Dowd K A, Cao B, Himansu S, Caine E A, Nunes B T D, Medeiros D B A, et al. Vaccine mediated protection against Zika virus-induced congenital disease. *Cell*. 2017;170:273–283.e12. doi: 10.1016/j.cell.2017.06.040. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [19] Arunachalam P S, Scott M K D, Hagan T, Li C F, Feng Y P, Wimmers F, Grigoryan L, Trisal M, Edara V V, Lai L, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. *Nature*. 2021;596:410–416. doi: 10.1038/s41586-021-03791-x. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [20] Wadman M. The overlooked superpower of mRNA vaccines. *Science*. 2021;373:479. doi: 10.1126/science.373.6554.479. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [21] Huang X, Xu W G, Li M Q, Zhang P, Zhang Y S, Ding J X, Chen X S. Antiviral biomaterials. *Matter*. 2021;4:1892–1918. doi: 10.1016/j.matt.2021.03.016. [[CrossRef](#)] [[Google Scholar](#)]
- [22] Selmi A, Vascotto F, Kautz-Neu K, Türeci Ö, Sahin U, von Stebut E, Diken M, Kreiter S. Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. *Cancer Immunol. Immunother.* 2016;65:1075–1083. doi: 10.1007/s00262-016-1869-7. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [23] Granstein R D, Ding W H, Ozawa H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. *J. Invest. Dermatol.* 2000;114:632–636. doi: 10.1046/j.1523-1747.2000.00929.x. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [24] Sahin U, Derhovanessian E, Miller M, Kloke B P, Simon P, Löwer M, Bukur V, Tadmor A D, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize polyspecific therapeutic immunity against cancer. *Nature*. 2017;547:222–226. doi: 10.1038/nature23003. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]



[25] Kreiter S, Selmi A, Diken M, Koslowski M, Britten C M, Huber C, Türeci Ö, Sahin U. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. *Cancer Res.* 2010;70:9031–9040. doi: 10.1158/0008-5472.CAN-10-0699. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[26] Kowalski P S, Rudra A, Miao L, Anderson D G. Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. *Mol. Ther.* 2019;27:710–728. doi: 10.1016/j.ymthe.2019.02.012. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[27] Kaczmarek J C, Patel A K, Kauffman K J, Fenton O S, Webber M J, Heartlein M W, DeRosa F, Anderson D G. Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs. *Angew. Chem., Int. Ed.* 2016;55:13808–13812. doi: 10.1002/anie.201608450. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[28] Guimaraes P P G, Zhang R, Spektor R, Tan M, Chung A, Billingsley M M, El-Mayta R, Riley R S, Wang L L, Wilson J M, et al. Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated *in vivo* delivery screening. *J. Control. Release.* 2019;316:404–417. doi: 10.1016/j.jconrel.2019.10.028. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[29] Yan H M, Hu Y, Akk A, Rai M F, Pan H, Wickline S A, Pham C T N. Induction of WNT16 via peptide-mRNA nanoparticle-based delivery maintains cartilage homeostasis. *Pharmaceutics.* 2020;12:73. doi: 10.3390/pharmaceutics12010073. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[30] Jiang Y H, Lu Q, Wang Y H, Xu E, Ho A, Singh P, Wang Y F, Jiang Z Z, Yang F, Tietjen G T, et al. Quantitating endosomal escape of a library of polymers for mRNA delivery. *Nano Lett.* 2020;20:1117–1123. doi: 10.1021/acs.nanolett.9b04426. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[31] Sharifnia Z, Bandehpour M, Hamishehkar H, Mosaffa N, Kazemi B, Zarghami N. *In-vitro* transcribed mRNA delivery using PLGA/PEI nanoparticles into human monocyte-derived dendritic cells. *Iran. J. Pharm. Res.* 2019;18:1659–1675. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

[32] Vaidyanathan S, Azizian K T, Haque A K M A, Henderson J M, Hendel A, Shore S, Antony J S, Hogrefe R I, Kormann M S D, Porteus M H, et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. *Mol. Ther. Nucleic Acids.* 2018;12:530–542. doi: 10.1016/j.omtn.2018.06.010. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[33] Lee A S Y, Kranzusch P J, Doudna J A, Cate J H D. eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation. *Nature.* 2016;536:96–99. doi: 10.1038/nature18954. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

- [34] Martin S A, Paoletti E, Moss B. Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. *J. Biol. Chem.* 1975;250:9322–9329. doi: 10.1016/S0021-9258(19)40646-7. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [35] Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads R E. Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. *RNA.* 2001;7:1486–1495. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
- [36] von Niessen A G O, Poleganov M A, Rechner C, Plaschke A, Kranz L M, Fesser S, Diken M, Löwer M, Vallazza B, Beisert T, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3' UTRs identified by cellular library screening. *Mol. Ther.* 2019;27:824–836. doi: 10.1016/j.ymthe.2018.12.011. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [37] Stefanovic B, Hellerbrand C, Brenner D A. Regulatory role of the conserved stem-loop structure at the 5' end of collagen  $\alpha 1(I)$  mRNA. *Mol. Cell. Biol.* 1999;19:4334–4342. doi: 10.1128/MCB.19.6.4334. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [38] Wu X Y, Brewer G. The regulation of mRNA stability in mammalian cells: 2.0. *Gene.* 2012;500:10–21. doi: 10.1016/j.gene.2012.03.021. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [39] Choi Y H, Hagedorn C H. Purifying mRNAs with a high-affinity eIF4E mutant identifies the short 3' poly(A) end phenotype. *Proc. Natl. Acad. Sci. USA.* 2003;100:7033–7038. doi: 10.1073/pnas.1232347100. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [40] Jalkanen A L, Coleman S J, Wilusz J. Determinants and implications of mRNA poly(A) tail size-does this protein make my tail look big? *Semin. Cell Dev. Biol.* 2014;34:24–32. doi: 10.1016/j.semcd.2014.05.018. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [41] Zhong Z F, Portela Catani J P, Mc Cafferty S, Couck L, Van Den Broeck W, Gorlé N, Vandenbroucke R E, Devriendt B, Ulbert S, Cnops L, et al. Immunogenicity and protection efficacy of a naked self-replicating mRNA-based Zika virus vaccine. *Vaccines.* 2019;7:96. doi: 10.3390/vaccines7030096. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [42] Li W, Meng J L, Ma X H, Lin J Q, Lu X G. Advanced materials for the delivery of vaccines for infectious diseases. *Biosaf. Health.* 2022;4:95–104. doi: 10.1016/j.bsheal.2022.03.002. [[CrossRef](#)] [[Google Scholar](#)]

[43] Qiu P, Ziegelhoffer P, Sun J, Yang N S. Gene gun delivery of mRNA *in situ* results in efficient transgene expression and genetic immunization. *Gene Ther.* 1996;3:262–268. [[PubMed](#)] [[Google Scholar](#)]

[44] De Ravin S S, Reik A, Liu P Q, Li L H, Wu X L, Su L, Raley C, Theobald N, Choi U, Song A H, et al. Targeted gene addition in human CD34<sup>+</sup> hematopoietic cells for correction of X-linked chronic granulomatous disease. *Nat. Biotechnol.* 2016;34:424–429. doi: 10.1038/nbt.3513. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[45] Hu B, Li B, Li K, Liu Y Y, Li C H, Zheng L L, Zhang M J, Yang T R, Guo S, Dong X Y, et al. Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia. *Sci. Adv.* 2022;8:eab–1418. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

[46] Li C H, Yang T R, Weng Y H, Zhang M J, Zhao D Y, Guo S, Hu B, Shao W X, Wang X X, Hussain A, et al. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. *Bioact. Mater.* 2022;9:590–601. doi: 10.1016/j.bioactmat.2021.05.051. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[47] Li C H, Zhou J H, Wu Y D, Dong Y L, Du L L, Yang T R, Wang Y H, Guo S, Zhang M J, Hussain A, et al. Core role of hydrophobic core of polymeric nanomicelle in endosomal escape of siRNA. *Nano Lett.* 2021;21:3680–3689. doi: 10.1021/acs.nanolett.0c04468. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[48] Yang T R, Li C H, Wang X X, Zhao D Y, Zhang M J, Cao H Q, Liang Z C, Xiao H H, Liang X J, Weng Y H, et al. Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle. *Bioact. Mater.* 2020;5:1053–1061. doi: 10.1016/j.bioactmat.2020.07.003. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[49] Zhang Y Q, Li Z Y, Essola J M, Ge K, Dai X Y, He H N, Xiao H H, Weng Y H, Huang Y Y. Biosafety materials: Ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system. *Biosaf. Health.* 2022;4:70–78. doi: 10.1016/j.bshealth.2022.03.010. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[50] Ullah A, Chen G, Yibang Z, Hussain A, Shafiq M, Raza F, Liu D J, Wang K K, Cao J, Qi X Y. A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis. *Biomater. Sci.* 2022;10:2650–2664. doi: 10.1039/D2BM00242F. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[51] Guo S, Li K, Hu B, Li C H, Zhang M J, Hussain A, Wang X X, Cheng Q, Yang F, Ge K, et al. Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment. *Exploration.* 2021;1:35–49. doi: 10.1002/EXP.20210008. [[CrossRef](#)] [[Google Scholar](#)]



[52] Huang, C. G.; Zhang, H. L.; Hussain, A. Liposome formulation of fluticasone furoate and method of preparation. U. S. Patent 11304901, April 19, 2022.

[53] Semple S C, Akinc A, Chen J X, Sandhu A P, Mui B L, Cho C K, Sah D W Y, Stebbing D, Crosley E J, Yaworski E, et al. Rational design of cationic lipids for siRNA delivery. *Nat. Biotechnol.* 2010;28:172–176. doi: 10.1038/nbt.1602. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[54] Maier M A, Jayaraman M, Matsuda S, Liu J, Barros S, Querbes W, Tam Y K, Ansell S M, Kumar V, Qin J, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. *Mol. Ther.* 2013;21:1570–1578. doi: 10.1038/mt.2013.124. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[55] Kauffman K J, Dorkin J R, Yang J H, Heartlein M W, DeRosa F, Mir F F, Fenton O S, Anderson D G. Optimization of lipid nanoparticle formulations for mRNA delivery *in vivo* with fractional factorial and definitive screening designs. *Nano Lett.* 2015;15:7300–7306. doi: 10.1021/acs.nanolett.5b02497. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[56] Cheng Q, Wei T, Jia Y M, Farbiak L, Zhou K J, Zhang S Y, Wei Y L, Zhu H, Siegwart D J. Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. *Adv. Mater.* 2018;30:e1805308. doi: 10.1002/adma.201805308. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[57] Pardi N, Hogan M J, Pelc R S, Muramatsu H, Andersen H, DeMaso C R, Dowd K A, Sutherland L L, Scarce R M, Parks R, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. *Nature.* 2017;543:248–251. doi: 10.1038/nature21428. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[58] Jayaraman M, Ansell S M, Mui B L, Tam Y K, Chen J X, Du X Y, Butler D, Eltepu L, Matsuda S, Narayanannair J K, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing *in vivo*. *Angew. Chem., Int. Ed.* 2012;51:8529–8533. doi: 10.1002/anie.201203263. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[59] Yanez Arteta M, Kjellman T, Bartesaghi S, Wallin S, Wu X Q, Kvist A J, Dabkowska A, Székely N, Radulescu A, Bergenholtz J, et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. *Proc. Natl. Acad. Sci. USA.* 2018;115:E3351–E3360. doi: 10.1073/pnas.1720542115. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[60] Robinson E, MacDonald K D, Slaughter K, McKinney M, Patel S, Sun C, Sahay G. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. *Mol. Ther.* 2018;26:2034–2046. doi: 10.1016/j.ymthe.2018.05.014. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

- [61] DeRosa F, Guild B, Karve S, Smith L, Love K, Dorkin J R, Kauffman K J, Zhang J, Yahalom B, Anderson D G, et al. Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. *Gene Ther.* 2016;23:699–707. doi: 10.1038/gt.2016.46. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [62] Yin H, Song C Q, Dorkin J R, Zhu L J, Li Y X, Wu Q Q, Park A, Yang J, Suresh S, Bizhanova A, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components *in vivo*. *Nat. Biotechnol.* 2016;34:328–333. doi: 10.1038/nbt.3471. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [63] Cebecauer M, Amaro M, Jurkiewicz P, Sarmiento M J, Šachl R, Cwiklik L, Hof M. Membrane lipid nanodomains. *Chem. Rev.* 2018;118:11259–11297. doi: 10.1021/acs.chemrev.8b00322. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [64] Xuexiang H, Hanwen Z, Kamila B, Kelsey L S, Mohamad G A, Drew W, Michael J M. An ionizable lipid toolbox for RNA delivery. *Nature Communications.* 2021;12:7233. doi: 10.1038/s41467-021-27493-0. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [65] Buschmann M D, Carrasco M J, Alishetty S, Paige M, Alameh M G, Weissman D. Nanomaterial delivery systems for mRNA vaccines. *Vaccines.* 2021;9:65. doi: 10.3390/vaccines9010065. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [66] Li M, Zhao M N, Fu Y, Li Y, Gong T, Zhang Z R, Sun X. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. *J. Control. Release.* 2016;228:9–19. doi: 10.1016/j.jconrel.2016.02.043. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [67] Miyazaki T, Uchida S, Nagatoishi S, Koji K, Hong T, Fukushima S, Tsumoto K, Ishihara K, Kataoka K, Cabral H. Polymeric nanocarriers with controlled chain flexibility boost mRNA delivery *in vivo* through enhanced structural fastening. *Adv. Healthc. Mater.* 2020;9:e2000538. doi: 10.1002/adhm.202000538. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [68] Li M, Li Y, Peng K, Wang Y, Gong T, Zhang Z R, He Q, Sun X. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. *Acta Biomater.* 2017;64:237–248. doi: 10.1016/j.actbio.2017.10.019. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [69] Zhang M J, Weng Y H, Cao Z Y, Guo S, Hu B, Lu M, Guo W S, Yang T R, Li C H, Yang X Z, Huang Y Y. ROS-activatable siRNA-engineered polyplex for NIR-triggered synergistic cancer treatment. *ACS Appl. Mater. Interfaces.* 2020;12:32289–32300. doi: 10.1021/acsami.0c06614. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

- [70] Démoulins T, Milona P, Englezou P C, Ebensen T, Schulze K, Suter R, Pichon C, Midoux P, Guzmán C A, Ruggli N, et al. Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. *Nanomedicine*. 2016;12:711–722. doi: 10.1016/j.nano.2015.11.001. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [71] Kaczmarek J C, Kauffman K J, Fenton O S, Sadtler K, Patel A K, Heartlein M W, DeRosa F, Anderson D G. Optimization of a degradable polymer-lipid nanoparticle for potent systemic delivery of mRNA to the lung endothelium and immune cells. *Nano Lett*. 2018;18:6449–6454. doi: 10.1021/acs.nanolett.8b02917. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [72] Fenton O S, Kauffman K J, McClellan R L, Kaczmarek J C, Zeng M D, Andresen J L, Rhym L H, Heartlein M W, DeRosa F, Anderson D G. Customizable lipid nanoparticle materials for the delivery of siRNAs and mRNAs. *Angew. Chem., Int. Ed*. 2018;57:13582–13586. doi: 10.1002/anie.201809056. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [73] Ullah A, Chen G, Hussain A, Khan H, Abbas A, Zhou Z W, Shafiq M, Ahmad S, Ali U, Usman M, et al. Cyclam-modified polyethylenimine for simultaneous TGF $\beta$  siRNA delivery and CXCR4 inhibition for the treatment of CCl<sub>4</sub>-induced liver fibrosis. *Int. J. Nanomedicine*. 2021;16:4451–4470. doi: 10.2147/IJN.S314367. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [74] Akinc A, Maier M A, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Du X Y, Hope M J, Madden T D, et al. The Onpatro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. *Nat. Nanotechnol*. 2019;14:1084–1087. doi: 10.1038/s41565-019-0591-y. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [75] Sedic M, Senn J J, Lynn A, Laska M, Smith M, Platz S J, Bolen J, Hoge S, Bulychev A, Jacquinet E, et al. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. *Vet. Pathol*. 2018;55:341–354. doi: 10.1177/0300985817738095. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [76] Nabhan J F, Wood K M, Rao V P, Morin J, Bhamidipaty S, LaBranche T P, Gooch R L, Bozal F, Bulawa C E, Guild B C. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia. *Sci. Rep*. 2016;6:20019. doi: 10.1038/srep20019. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [77] Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega J B, Karmali P P, Chivukula P, Verma I M. Systemic delivery of factor IX messenger RNA for protein replacement therapy. *Proc. Natl. Acad. Sci. USA*. 2017;114:e1941–e1950. doi: 10.1073/pnas.1619653114. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[78] Kauffman K J, Mir F F, Jhunjhunwala S, Kaczmarek J C, Hurtado J E, Yang J H, Webber M J, Kowalski P S, Heartlein M W, DeRosa F, et al. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles *in vivo*. *Biomaterials*. 2016;109:78–87. doi: 10.1016/j.biomaterials.2016.09.006. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[79] Oberli M A, Reichmuth A M, Dorkin J R, Mitchell M J, Fenton O S, Jaklenec A, Anderson D G, Langer R, Blankschtein D. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. *Nano Lett*. 2017;17:1326–1335. doi: 10.1021/acs.nanolett.6b03329. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[80] Sago C D, Lokugamage M P, Paunovska K, Vanover D A, Monaco C M, Shah N N, Gamboa Castro M, Anderson S E, Rudoltz T G, Lando G N, et al. High-throughput *in vivo* screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. *Proc. Natl. Acad. Sci. USA*. 2018;115:E9944–E9952. doi: 10.1073/pnas.1811276115. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[81] Li B, Luo X, Deng B B, Giancola J B, McComb D W, Schmittgen T D, Dong Y Z. Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA. *Sci. Rep*. 2016;6:22137. doi: 10.1038/srep22137. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[82] Jain R, Frederick J P, Huang E Y, Burke K E, Mauger D M, Andrianova E A, Farlow S J, Siddiqui S, Pimentel J, Cheung-Ong K, et al. MicroRNAs enable mRNA therapeutics to selectively program cancer cells to self-destruct. *Nucleic Acid Ther*. 2018;28:285–296. doi: 10.1089/nat.2018.0734. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[83] Fenton O S, Kauffman K J, McClellan R L, Appel E A, Dorkin J R, Tibbitt M W, Heartlein M W, DeRosa F, Langer R, Anderson D G. Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent *in vivo* mRNA delivery. *Adv. Mater*. 2016;28:2939–2943. doi: 10.1002/adma.201505822. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[84] Fenton O S, Kauffman K J, Kaczmarek J C, McClellan R L, Jhunjhunwala S, Tibbitt M W, Zeng M D, Appel E A, Dorkin J R, Mir F F, et al. Synthesis and biological evaluation of ionizable lipid materials for the *in vivo* delivery of messenger RNA to B lymphocytes. *Adv. Mater*. 2017;29:1606944. doi: 10.1002/adma.201606944. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[85] Kowalski P S, Capasso Palmiero U, Huang Y X, Rudra A, Langer R, Anderson D G. Ionizable amino-polyesters synthesized via ring opening polymerization of tertiary amino-alcohols for tissue selective mRNA delivery. *Adv. Mater*. 2018;30:e1801151.

doi: 10.1002/adma.201801151. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[86] Jiang L, Berraondo P, Jericó D, Guey L T, Sampedro A, Frassetto A, Benenato K E, Burke K, Santamaría E, Alegre M, et al. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. *Nat. Med.* 2018;24:1899–1909. doi: 10.1038/s41591-018-0199-z. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[87] An D, Schneller J L, Frassetto A, Liang S, Zhu X L, Park J S, Theisen M, Hong S J, Zhou J, Rajendran R, et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. *Cell Rep.* 2017;21:3548–3558. doi: 10.1016/j.celrep.2017.11.081. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[88] Li B, Luo X, Deng B B, Wang J F, McComb D W, Shi Y M, Gaensler K M L, Tan X, Dunn A L, Kerlin B A, et al. An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery *in vivo*. *Nano Lett.* 2015;15:8099–8107. doi: 10.1021/acs.nanolett.5b03528. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[89] Turnbull I C, Eltoukhy A A, Fish K M, Nonnenmacher M, Ishikawa K, Chen J Q, Hajjar R J, Anderson D G, Costa K D. Myocardial delivery of lipidoid nanoparticle carrying modRNA induces rapid and transient expression. *Mol. Ther.* 2016;24:66–75. doi: 10.1038/mt.2015.193. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[90] Miller J B, Zhang S Y, Kos P, Xiong H, Zhou K J, Perelman S S, Zhu H, Siegwart D J. Non-viral CRISPR/cas gene editing *in vitro* and *in vivo* enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. *Angew. Chem., Int. Ed.* 2017;56:1059–1063. doi: 10.1002/anie.201610209. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[91] Jarzębińska A, Pasewald T, Lambrecht J, Mykhaylyk O, Kümmerling L, Beck P, Hasenpusch G, Rudolph C, Plank C, Dohmen C. A single methylene group in oligoalkylamine-based cationic polymers and lipids promotes enhanced mRNA delivery. *Angew. Chem., Int. Ed.* 2016;55:9591–9595. doi: 10.1002/anie.201603648. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[92] Schrom E, Huber M, Aneja M, Dohmen C, Emrich D, Geiger J, Hasenpusch G, Herrmann-Janson A, Kretschmann V, Mykhailyk O, et al. Translation of angiotensin-converting enzyme 2 upon liver- and lung-targeted delivery of optimized chemically modified mRNA. *Mol. Ther. Nucleic Acids.* 2017;7:350–365. doi: 10.1016/j.omtn.2017.04.006. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[93] Ball R L, Hajj K A, Vizelman J, Bajaj P, Whitehead K A. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. *Nano Lett.* 2018;18:3814–3822. doi: 10.1021/acs.nanolett.8b01101. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]



- [94] Tanaka H, Nakatani T, Furihata T, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H. *In vivo* introduction of mRNA encapsulated in lipid nanoparticles to brain neuronal cells and astrocytes via intracerebroventricular administration. *Mol. Pharm.* 2018;15:2060–2067. doi: 10.1021/acs.molpharmaceut.7b01084. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [95] Sabnis S, Kumarasinghe E S, Salerno T, Mihai C, Ketova T, Senn J J, Lynn A, Bulychev A, McFadyen I, Chan J, et al. A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates. *Mol. Ther.* 2018;26:1509–1519. doi: 10.1016/j.ymthe.2018.03.010. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [96] Hassett K J, Benenato K E, Jacquinet E, Lee A, Woods A, Yuzhakov O, Himansu S, Deterling J, Geilich B M, Ketova T, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. *Mol. Ther. Nucleic Acids.* 2019;15:1–11. doi: 10.1016/j.omtn.2019.01.013. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [97] Luo X, Li B, Zhang X, Zhao W, Bratasz A, Deng B, McComb D W, Dong Y. Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents. *Nanoscale.* 2017;9:1575–1579. doi: 10.1039/C6NR08496F. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [98] Jiang C, Mei M, Li B, Zhu X R, Zu W H, Tian Y J, Wang Q N, Guo Y, Dong Y Z, Tan X. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and *pcsk9* *in vivo*. *Cell Res.* 2017;27:440–443. doi: 10.1038/cr.2017.16. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [99] Badiyan Z S, Berezhanskyy T, Utzinger M, Aneja M K, Emrich D, Erben R, Schüller C, Altpeter P, Ferizi M, Hasenpusch G, et al. Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration. *J. Control. Release.* 2016;239:137–148. doi: 10.1016/j.jconrel.2016.08.037. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [100] Hajj K A, Ball R L, Deluty S B, Singh S R, Strelkova D, Knapp C M, Whitehead K A. Branched-tail lipid nanoparticles potently deliver mRNA *in vivo* due to enhanced ionization at endosomal pH. *Small.* 2019;15:e1805097. doi: 10.1002/smll.201805097. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [101] Tanaka H, Watanabe A, Konishi M, Nakai Y, Yoshioka H, Ohkawara T, Takeda H, Harashima H, Akita H. The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid scaffolds. *Heliyon.* 2018;4:e00959. doi: 10.1016/j.heliyon.2018.e00959. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[102] McKinlay C J, Vargas J R, Blake T R, Hardy J W, Kanada M, Contag C H, Wender P A, Waymouth R M. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. *Proc. Natl. Acad. Sci. USA*. 2017;114:e448–e456. doi: 10.1073/pnas.1614193114. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[103] Patel A K, Kaczmarek J C, Bose S, Kauffman K J, Mir F, Heartlein M W, DeRosa F, Langer R, Anderson D G. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. *Adv. Mater.* 2019;31:e1805116. doi: 10.1002/adma.201805116. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[104] Van der Jeught K, De Koker S, Bialkowski L, Heirman C, Tjok Joe P, Perche F, Maenhout S, Bevers S, Broos K, Deswarte K, et al. Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety. *ACS Nano*. 2018;12:9815–9829. doi: 10.1021/acsnano.8b00966. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[105] Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler T K, Pawelec G, Hoerr I, Rammensee H G, Garbe C. Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. *J. Immunother.* 2009;32:498–507. doi: 10.1097/CJI.0b013e3181a00068. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[106] Armbruster N, Jasny E, Petsch B. Advances in RNA vaccines for preventive indications: A case study of a vaccine against rabies. *Vaccines*. 2019;7:132. doi: 10.3390/vaccines7040132. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[107] Jarzebska N T, Lauchli S, Iselin C, French L E, Johansen P, Guenova E, Kündig T M, Pascolo S. Functional differences between protamine preparations for the transfection of mRNA. *Drug Deliv.* 2020;27:1231–1235. doi: 10.1080/10717544.2020.1790692. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[108] Li M C, Wang H, Tian L L, Pang Z H, Yang Q K, Huang T Q, Fan J F, Song L H, Tong Y G, Fan H H. COVID-19 vaccine development: Milestones, lessons and prospects. *Signal Transduct. Target. Ther.* 2022;7:146. doi: 10.1038/s41392-022-00996-y. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[109] Hussain A, Yang H Y, Zhang M J, Liu Q, Alotaibi G, Irfan M, He H N, Chang J, Liang X J, Weng Y H, et al. mRNA vaccines for COVID-19 and diverse diseases. *J. Control. Release*. 2022;345:314–333. doi: 10.1016/j.jconrel.2022.03.032. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

- [110] Luk A, Clarke B, Dahdah N, Ducharme A, Krahn A, McCrindle B, Mizzi T, Naus M, Udell J A, Virani S, et al. Myocarditis and pericarditis after COVID-19 mRNA vaccination: Practical considerations for care providers. *Can. J. Cardiol.* 2021;37:1629–1634. doi: 10.1016/j.cjca.2021.08.001. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [111] Garcia-Beltran W F, St. Denis K J, Hoelzemer A, Lam E C, Nitido A D, Sheehan M L, Berrios C, Ofoman O, Chang C C, Hauser B M, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell.* 2022;185:457–466.e4. doi: 10.1016/j.cell.2021.12.033. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [112] Dong Y Z, Dorkin J R, Wang W H, Chang P H, Webber M J, Tang B C, Yang J, Abutbul-Ionita I, Danino D, DeRosa F, et al. Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery *in vivo*. *Nano Lett.* 2016;16:842–848. doi: 10.1021/acs.nanolett.5b02428. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [113] Palmiero U C, Kaczmarek J C, Fenton O S, Anderson D G. Poly( $\beta$ -amino ester)-co-poly(caprolactone) terpolymers as nonviral vectors for mRNA delivery *in vitro* and *in vivo*. *Adv. Healthc. Mater.* 2018;7:e1800249. doi: 10.1002/adhm.201800249. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [114] Li J H, Wang W D, He Y P, Li Y Z, Yan E Z, Zhang K T, Irvine D J, Hammond P T. Structurally programmed assembly of translation initiation nanoplex for superior mRNA delivery. *ACS Nano.* 2017;11:2531–2544. doi: 10.1021/acsnano.6b08447. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [115] Li J H, He Y P, Wang W D, Wu C, Hong C, Hammond P T. Polyamine-mediated stoichiometric assembly of ribonucleoproteins for enhanced mRNA delivery. *Angew. Chem., Int. Ed.* 2017;56:13709–13712. doi: 10.1002/anie.201707466. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [116] Haabeth O A W, Blake T R, McKinlay C J, Waymouth R M, Wender P A, Levy R. mRNA vaccination with chargealtering releasable transporters elicits human T cell responses and cures established tumors in mice. *Proc. Natl. Acad. Sci. USA.* 2018;115:e9153–e9161. doi: 10.1073/pnas.1810002115. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [117] McKinlay C J, Benner N L, Haabeth O A, Waymouth R M, Wender P A. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. *Proc. Natl. Acad. Sci. USA.* 2018;115:e5859–e5866. doi: 10.1073/pnas.1805358115. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

- [118] Le Moignic A, Malard V, Benvegna T, Lemiègre L, Berchel M, Jaffrès P A, Baillou C, Delost M, Macedo R, Rochefort J, et al. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. *J. Control. Release*. 2018;278:110–121. doi: 10.1016/j.jconrel.2018.03.035. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [119] Yan Y F, Xiong H, Zhang X Y, Cheng Q, Siegwart D J. Systemic mRNA delivery to the lungs by functional polyester-based carriers. *Biomacromolecules*. 2017;18:4307–4315. doi: 10.1021/acs.biomac.7b01356. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [120] Dunn A W, Kalinichenko V V, Shi D L. Highly efficient *in vivo* targeting of the pulmonary endothelium using novel modifications of polyethylenimine: An importance of charge. *Adv. Healthc. Mater.* 2018;7:e1800876. doi: 10.1002/adhm.201800876. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [121] Uchida S, Kinoh H, Ishii T, Matsui A, Tockary T A, Takeda K M, Uchida H, Osada K, Itaka K, Kataoka K. Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. *Biomaterials*. 2016;82:221–228. doi: 10.1016/j.biomaterials.2015.12.031. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [122] Chen Q X, Qi R G, Chen X Y, Yang X, Wu S D, Xiao H H, Dong W F. A targeted and stable polymeric nanoformulation enhances systemic delivery of mRNA to tumors. *Mol. Ther.* 2017;25:92–101. doi: 10.1016/j.ymthe.2016.10.006. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [123] Schumann C, Nguyen D X, Norgard M, Bortnyak Y, Korzun T, Chan S, Lorenz A S, Moses A S, Albarqi H A, Wong L, et al. Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA. *Theranostics*. 2018;8:5276–5288. doi: 10.7150/thno.27847. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [124] Jiang Y H, Gaudin A, Zhang J W, Agarwal T, Song E, Kauffman A C, Tietjen G T, Wang Y H, Jiang Z Z, Cheng C J, et al. A “top-down” approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery. *Biomaterials*. 2018;176:122–130. doi: 10.1016/j.biomaterials.2018.05.043. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [125] Fornaguera C, Guerra-Rebollo M, Ángel Lázaro M, Castells-Sala C, Meca-Cortés O, Ramos-Pérez V, Cascante A, Rubio N, Blanco J, Borrós S. mRNA delivery system for targeting antigen-presenting cells *in vivo*. *Adv. Healthc. Mater.* 2018;7:e1800335. doi: 10.1002/adhm.201800335. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- [126] Song Y, Wang M M, Li S Q, Jin H B, Cai X L, Du D, Li H, Chen C L, Lin Y H. Efficient cytosolic delivery using crystalline nanoflowers assembled from fluorinated

peptoids. *Small*. 2018;14:e1803544. doi: 10.1002/smll.201803544. [[PubMed](#)]  
[[CrossRef](#)] [[Google Scholar](#)]

[127] Chen G J, Ma B, Wang Y Y, Gong S Q. A universal GSH-responsive nanoplatform for the delivery of DNA, mRNA, and Cas9/sgRNA ribonucleoprotein. *ACS Appl. Mater. Interfaces*. 2018;10:18515–18523. doi: 10.1021/acsami.8b03496. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[128] Thomas S J, Moreira E D, Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez J L, Marc G P, Polack F P, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. *N. Engl. J. Med.* 2021;385:1761–1773. doi: 10.1056/NEJMoa2110345. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[129] El Sahly H M, Baden L R, Essink B, Doblecki-Lewis S, Martin J M, Anderson E J, Campbell T B, Clark J, Jackson L A, Fichtenbaum C J, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. *N. Engl. J. Med.* 2021;385:1774–1785. doi: 10.1056/NEJMoa2113017. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[130] Xu, Z. P.; Liu, K. F.; Gao, G. F. Omicron variant of SARS-CoV-2 imposes a new challenge for the global public health. *Biosaf. Health*, in press, 10.1016/j.bsheal.2022.01.002. [[PMC free article](#)] [[PubMed](#)]

[131] Zhang, B.; Huo, J.; Huang, Y.; Teo, S. Y.; Li, Y. F.; Toh, L. K.; Lam, K. P.; Xu, S. mRNA booster vaccination enhances antibody responses against SARS-CoV2 Omicron variant in individuals primed with mRNA or inactivated virus vaccines. **2022**.

[132] Wu K, Choi A, Koch M, Elbashir S, Ma L Z, Lee D, Woods A, Henry C, Palandjian C, Hill A, et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. *Vaccine*. 2021;39:7394–7400. doi: 10.1016/j.vaccine.2021.11.001. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[133] Dolgin E. CureVac COVID vaccine let-down spotlights mRNA design challenges. *Nature*. 2021;594:483. doi: 10.1038/d41586-021-01661-0. [[PubMed](#)]  
[[CrossRef](#)] [[Google Scholar](#)]

[134] Chen G L, Li X F, Dai X H, Li N, Cheng M L, Huang Z, Shen J, Ge Y H, Shen Z W, Deng Y Q, et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: A randomised, double-blind, placebo-controlled, phase 1 trial. *Lancet Microbe*. 2022;3:e193–e202. doi: 10.1016/S2666-5247(21)00280-9. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[135] Chaudhary N, Weissman D, Whitehead K A. mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. *Nat. Rev. Drug*



*Discov.* 2021;20:817–838. doi: 10.1038/s41573-021-00283-5. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[136] Hekele A, Bertholet S, Archer J, Gibson D G, Palladino G, Brito L A, Otten G R, Brazzoli M, Buccato S, Bonci A, et al. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. *Emerg. Microbes Infect.* 2013;2:e52. doi: 10.1038/emi.2013.54. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[137] Bahl K, Senn J J, Yuzhakov O, Bulychev A, Brito L A, Hassett K J, Laska M E, Smith M, Almarsson Ö, Thompson J, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. *Mol. Ther.* 2017;25:1316–1327. doi: 10.1016/j.ymthe.2017.03.035. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[138] Bian J W, Li Z J. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. *Acta Pharm. Sin. B.* 2021;11:1–12. doi: 10.1016/j.apsb.2020.10.006. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[139] Zhang P, Narayanan E, Liu Q B, Tsybovsky Y, Boswell K, Ding S L, Hu Z H, Follmann D, Lin Y, Miao H Y, et al. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. *Nat. Med.* 2021;27:2234–2245. doi: 10.1038/s41591-021-01574-5. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[140] Loomis R J, DiPiazza A T, Falcone S, Ruckwardt T J, Morabito K M, Abiona O M, Chang L A, Caringal R T, Presnyak V, Narayanan E, et al. Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate nipah vaccine. *Front. Immunol.* 2021;12:772864. doi: 10.3389/fimmu.2021.772864. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[141] Lamb, R. A. Paramyxoviridae: The viruses and their replication. *Fields Virology* **2001**.

[142] Fugl A, Andersen C L. Epstein—Barr virus and its association with disease—A review of relevance to general practice. *BMC Fam. Pract.* 2019;20:62. doi: 10.1186/s12875-019-0954-3. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[143] Kozlov M. Monkeypox goes global: Why scientists are on alert. *Nature.* 2022;606:15–16. doi: 10.1038/d41586-022-01421-8. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[144] Oladoye M J. Monkeypox: A neglected viral zoonotic disease. *Eur. J. Med. Educat. Technol.* 2021;14:e–2108. [[Google Scholar](#)]

[145] Nowak D, Jakubczyk E. The freeze-drying of foods—The characteristic of the process course and the effect of its parameters on the physical properties of food materials. *Foods*. 2020;9:1488. doi: 10.3390/foods9101488. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[146] Huang Y Y, Zheng S Q, Guo Z D, de Mollerat du Jeu X, Liang X J, Yang Z W, Zhang H Y, Gao S, Liang Z C. Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B. *Signal Transduct. Target. Ther.* 2022;7:38. doi: 10.1038/s41392-021-00859-y. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

[147] Ai, L. X.; Li, Y. F.; Zhou, L.; Zhang, H.; Yao, W. R.; Han, J. Y.; Wu, J. M.; Wang, R. Y.; Wang, W. J.; Xu, P. et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. 2022, bioRxiv 2022.02.10.479867.

[148] Muramatsu H, Lam K, Bajusz C, Laczkó D, Karikó K, Schreiner P, Martin A, Lutwyche P, Heyes J, Pardi N. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. *Mol. Ther.* 2022;30:1941–1951. doi: 10.1016/j.ymthe.2022.02.001. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]

It was Bill Gates of Microsoft who told Becky Quick of MSNBC at Davos, Switzerland three years ago that his investment in vaccines was a great investment opportunity, and has paid off 20-to-1. He has so many investments in vaccine technology that he has to have a manager of his investments in virus technology. Go figure how much you could have made with that kind of return. A \$10-million investment could return a profit of \$200 million. This is the reason they are going to never quit at drumming up viruses, variants, mutants, that will require a new series of vaccines.

It is sort of like the Hegelian Dialectic – “Thesis-Antithesis-Synthesis” or in everyday terms, “Problem-Reaction-Solution”.

The [Hegelian](#) dialectical formula: A (thesis) versus B (anti-thesis) equals C (synthesis). For example: **If (A) my idea of freedom conflicts with (B) your idea of freedom then (C) neither of us can be free until everyone agrees to be a slave.** The Soviet Union was based on the Hegelian dialectic, as is all [Marxist](#) writing.

I am indebted to my History professor and mentor at Waynesburg College in Pennsylvania for my knowledge and interest in how humanity is manipulated to perform on que by those wanting to enslave us, steal from us, rob us of life, liberty and the pursuit of our dreams and goals.

# Hegelian Dialectic



## Agenda

Satanic New World Order  
Global Mass Murder



## Thesis

Communism, Socialism,  
Bolsheviks



## Anti-Thesis


National Socialism,  
Fascism, NaZis

## Synthesis

Oligarchy enriched by endless concocted war,  
Destruction of democratic/ecclesiastical institutions,  
Global Gulag and Genocide

Zionists Betrayed Jews to Holocaust

<http://wariscrime.com/new/zionists-betrayed-jews-to-holocaust/>



Need I remind you that Covid-19 was pre-planned decades ago for the purpose of fear-mongering the public to take their poisoned vaxxes that are filled with nano-particles bearing unwanted gifts intended to weaken and destroy their God-given immune systems.

These so-called vaxxes are nothing but “gene” therapy that changes your DNA through a technology known as CRISPR-Cas9. They are given under EAU or Emergency Application Use. However, if you die you are considered to have voluntarily committed suicide. Insurance companies are beginning to deny death and injury claims under that provision of the law. If you survive these shots you are unable to sue for damages because you signed a release document that nullifies the vaxx maker of any liability.

### **Bill Gates Admits Covid Is A “Disease Mainly Of The Elderly...Kind Of Like The Flu”**

[Fact checked](#)

#### **GATES EVEN ADMITS THE VACCINES DON'T BLOCK TRANSMISSION**

[August 8, 2022 Niamh Harris News,](#)

**Despite pushing lockdowns and experimental vaccines and helping destroy the world's economies, Bill Gates recently made some stunning admissions regarding Covid.**

He said that the [virus was a lot like the flu and that it affected mostly elderly people](#) and that it had a low fatality rate.

His words were remarkably similar to some of the world's top lockdown opponents who were saying the very same things since the start of the so called pandemic..

#### [Bill Gates Developing Vaccine That Spreads ‘Like a Virus’ To Vaccinate People Without Consent](#)

[YouTube Video VVV6MkVGRnQxczFuc091bmhwRnNHQk9RLkVad0F5STNScE1n](#)

#### **Bill Gates Developing Vaccine That Spreads ‘Like a Virus’ To Vaccinate People Without Consent**

August 1, 2022 9:14 pm

[Need to Know](#) reports: Jimmy Dore pointed out that the average age of people who were diagnosed as dying from COVID was above the life expectancy rate. Gates also admitted that COVID ‘vaccines’ do not block transmission.

#### **Analysis from Jimmy Dore:**

While Jimmy Dore subscribes to the virus theory of COVID, he does make some important points, including the fact that the average age of people who supposedly died from COVID is over the age of life expectancy! The [average lifespan](#) for a male in the US is 79 years of age, but the average age of people who died from COVID was 81.5 years of age. Dore acknowledged that it is impossible to find the actual death rate from 2020 and an account of how many people died *from* COVID rather than *with* COVID. The government's VAERS report has the average age of death at 74 years of age.

Warning: there is some rough and vulgar language.

Full Video Interview can be found on the News Punch web site.

Sobering statements and admissions from Bill Gates in the video listed below with time stamps:

2:02 Gates promotes depopulation through birth control and said that if you improve health in poor countries, people will have only 2 children to support them in old age, instead of larger families.

12:25 Gates praised the “ruthless” contract tracing by South Korea and claims that is why it had fewer COVID deaths.

13:15 Gates recommended elderly people get vaccinated and that masks should not be viewed as a “deep infringement of freedom.”

17:50 Gates agreed that Americans should accept some restrictions on our liberties.

23:40 Gates said that in early February 2020, he was in a meeting and experts at his foundation said that there had been too much travel without a diagnosis for COVID to be contained. He said, “then, at that point, we didn’t really understand that the fatality rate, you know, we didn’t understand that it’s a fairly low fatality rate. And that it’s a disease mainly of the elderly, kind of like flu is, although a bit different than that.”

28:04 Gates said that there had never been a commercial product using mRNA, so it’s wild that it was developed so fast. He said that the COVID vaccines are imperfect in two very important ways, one, they don’t block infection. They were hoping that the vaccines would create enough antibodies in the upper respiratory tract that vaccinated people wouldn’t get infected. Said young people who don’t get very sick should take vaccines to take them out of the transmission chains.

28:50 He said that the duration of protection from COVID vaccines is going down, especially for people in their 70s, it only lasts about 5 months.

**Steve Kirsch posted a tweet in which the Saudi ambassador to Egypt on Tuesday, August 8<sup>th</sup>, 2022, Muhammad al-Qahtani, fell backwards and died during a speech at a conference in the Egyptian capital, Cairo, in which he praised president A-Sisi and described him as “*the dean of humanity.*”**

**The Saudi ambassador falls back and dies instantly in public view.** Yet another death in plain sight. These deaths are common after the “*safe and effective*” COVID vaccines were rolled out. Reality: you increase your risk of injury/death by over 20X. It is shocking how many vehicle accidents and swimming incidents are related to deaths following being vaccinated.

If you take the time to watch Dr. David L. Martin’s interview mentioned above it will not take long to conclude this is the “Final Solution” being carried out to “Depopulate” the world, as it was plainly enshrined in granite stone tablets down in Elberton, Georgia. For forty years the Georgia Guidestones stood as a beacon of “Eugenics” until it was



mysteriously bombed two months ago and then removed by a construction crew hours later.

Speaking about the “Final Solution” the global scientists are developing a pill version of the mRNA Spike Protein. This is going to be the offering to the vaxx syringe needle resisters. It is being developed by a British artificial intelligence company called DeepMind Technologies, which is a subsidiary of Alphabet, Inc. (Google). They have developed HexaPro prefusion spike protein stabilizer.

Their latest system of computerized artificial intelligence is programmed in predicting the 3D structure of proteins from sequences of amino acids, their subsequent folds, and goes by the name of AlphaFold AI.

The global agenda goal is not a benevolent solution to the SARS-CoV2 “man-made” virus. It will be a delivery system by way of “vaccines” that permanently alters the God-given design of each and every human’s DNA. Thus, condemning their soul to perdition for all of eternity, for their DNA is their actual name. I want you to think about this for a moment. “Your DNA is your real name!” You may have a name that your parents may have named you, in my case I am named after my uncle and my grandfather on my mother’s side of the family. But my name written in God’s Book of Life” is my DNA. **“And whosoever was not found written in the book of life was cast into the lake of fire.”** –(Revelation 20:15).

The convenient “final solution” to be offered to those not yet “vaxxed” against SARS-CoV2, will be a sub-unit protein contained within a self-applied microneedle array patch. Bill Gates as part of his ID2020 plan showed this microneedle array patch a few years ago and in previous segments I have shown illustrations of the patch technology.

From the very beginning recipients of their first injection of any “vaccine” for SARS-CoV2 received the “Mark” of the Beast. The microneedle array patch delivery system comes later in the process and simply makes the process of receiving these technologies more conveniently for the syringe needle resisters. The initial vaccines are merely what the body recognizes as a third strand DNA segment which is then transcribed back into the DNA as RNA. The spike protein is built from amino acids, a sequence that is read by the AlphaFold AI from PDBs of existing coronavirus proteins, and thus synthesizing a new spike protein for the synthetic SARS-CoV2.

Reverse translation of these amino acids results in determining the base pair nucleotides building out as RNA. The single-strand sequence of RNA can be reverse transcribed into DNA. This defines what the entire chimeric DNA sequence will manifest as. Covid-19 became a Retrovirus once injected into the human body recipient at the time of receiving the jab.

Typically, the resultant chimeric DNA sequence would be the sequence resulting from the integration of genomic materials of the virus itself, into the host DNA. In this case, it is the reverse, with the sequence of chimeric DNA being defined by the RNA that was

translated from the amino acid sequence of the synthetic spike protein predicted and built using AlphaFold AI.

From this chimeric DNA, ordinary transcription of the DNA to RNA can take place within the nucleus. This transcribed RNA is the final product. It is the SARS-CoV2 virus itself. Thus, the AlphaFold AI designed the virus by first designing the spike protein that the virus displays around the surface membrane. Spike protein, to virus via AlphaFold AI. The name they have given this neuromorphic artificial intelligence AI is actually called "TRANSFORMER". The implications are obvious!

Over the past twenty months various spokes-people from the biochemical world or scientific community have made statements to the effect that the spike protein does not remain in the body for very long. However, the substance for these statements remains dubious at best and certainly unproven for very long. Suggestions from 90 days to six months have not been backed up with any confirming evidence.

Specifically, with respect to DNA, RNA, proteins and their *in vitro*, *in vivo* and *in silico* synthetic modifications culminating in the SARS-CoV2 "vaccine" delivery of the DNA-altering "Mark" of the Beast, found in Revelation 13:17 of the Bible, some individuals may have wanted to lessen the impact or dispute the vaxx as being the Biblical "Mark" of the Beast as a way to lessen the fear by Christians who may have regretted taken the vaxxes under duress for travel, school, and work. That said, for the FDA to approve vaxxes for children under the age of five is blatantly criminal under its shabby justification since there is no pandemic crisis for children and teens. The FDA acted arbitrarily and without concern for safety or life of the young.

The conclusion that Dr. David L. Martin makes in the interview above can be best described as "Crimes Against Humanity!" That fact becomes obvious when we have previously analyzed the medical community and its prescribed treatment of those admitted for treatment of Covid-19.

Upon admission to a once-trusted hospital, American patients with COVID-19 become virtual prisoners, subjected to a rigid treatment protocol with roots in Ezekiel Emanuel's "*Complete Lives System*" for rationing medical care in those over age 50. They have a shockingly high mortality rate. How and why is this happening, and what can be done about it?

As [exposed in audio recordings](#), hospital executives in Arizona admitted meeting several times a week to *lower* standards of care, with coordinated restrictions on visitation rights. Most COVID-19 patients' families are deliberately kept in the dark about what is really being done to their loved ones.

The combination that enables this tragic and avoidable loss of hundreds of thousands of lives includes (1) The [CARES Act](#), which provides hospitals with bonus incentive payments for all things related to COVID-19 (testing, diagnosing, admitting to hospital, use of remdesivir and ventilators, reporting COVID-19 deaths, and vaccinations) and

(2) [waivers of customary and long-standing patient rights](#) by the Centers for Medicare and Medicaid Services (CMS).

In 2020, the [Texas Hospital Association](#) submitted requests for waivers to CMS. According to Texas attorney Jerri Ward, “CMS has granted ‘waivers’ of federal law regarding patient rights. Specifically, CMS purports to allow hospitals to violate the rights of patients or their surrogates with regard to medical record access, to have patient visitation, and to be free from seclusion.” She notes that “rights do not come from the hospital or CMS and cannot be waived, as that is the antithesis of a ‘right.’ The purported waivers are meant to isolate and gain total control over the patient and to deny patient and patient’s decision-maker the ability to exercise informed consent.”

Creating a “National Pandemic Emergency” provided justification for such sweeping actions that override individual physician medical decision-making and patients’ rights. The CARES Act provided incentives for hospitals to use treatments dictated solely by the federal government under the auspices of the NIH. These “bounties” must be paid back if not “earned” by making the COVID-19 diagnosis and following the COVID-19 protocol. THE GOVERNMENT PAID HOSPITALS GENEROUSLY TO KILL COVID-19 VICTIMS. THIS IS NOT EVEN DEBATABLE, IT IS WELL-DOCUMENTED EVIDENCE.

The hospital payments include:

- A “free” *required* PCR test in the Emergency Room or upon admission for every patient, with government-paid fee to hospital.
- Added bonus payment for each positive COVID-19 diagnosis.
- Another bonus for a COVID-19 admission to the hospital.
- A 20 percent “boost” bonus payment from Medicare on the *entire hospital bill* for use of remdesivir instead of medicines such as Ivermectin.
- Another and larger bonus payment to the hospital if a COVID-19 patient is mechanically ventilated.
- More money to the hospital if cause of death is listed as COVID-19, even if patient did not die directly of COVID-19.
- A COVID-19 diagnosis also provides extra payments to coroners.

CMS implemented “value-based” payment programs that track data such as how many workers at a healthcare facility receive a COVID-19 vaccine. Now we see why many hospitals implemented COVID-19 vaccine mandates. They are paid more to do so.

Outside hospitals, physician MIPS quality metrics link doctors’ income to performance-based pay for treating patients with COVID-19 EUA drugs. Failure to report information to CMS can cost the physician 4% of reimbursement.

Because of obfuscation with medical coding and legal jargon, we cannot be certain of the actual amount each hospital receives per COVID-19 patient. But Attorney Thomas Renz and CMS whistleblowers have calculated a total payment of at least \$100,000 per patient.

What does this mean for your health and safety as a patient in the hospital? Think about the fact that re-infections of COVID are spiking to levels that will likely see an increase of victims going to local hospitals.

There are deaths from the government-directed COVID treatments. For remdesivir, studies show that 71–75 percent of patients suffer an adverse effect, and the drug often had to be stopped after five to ten days because of these effects, such as kidney and liver damage, and death. Remdesivir trials during the 2018 West African Ebola outbreak had to be discontinued because *death rate exceeded 50%*. Yet, in 2020, it was Dr. Anthony Fauci who directed that remdesivir was to be the drug hospitals use to treat COVID-19, even when the COVID clinical trials of remdesivir showed similar adverse effects.

In ventilated patients, the death toll is staggering. A National Library of Medicine January 2021 report of 69 studies involving more than 57,000 patients concluded that fatality rates were 45 percent in COVID-19 patients receiving invasive mechanical ventilation, increasing to 84 percent in older patients. Renz announced at a [Truth for Health Foundation Press Conference](#) that CMS data showed that in Texas hospitals, 84.9% percent of all patients died after more than 96 hours on a ventilator.

Then there are deaths from restrictions on effective treatments for hospitalized patients. Renz and a team of data analysts have estimated that more than 800,000 deaths in America's hospitals, in COVID-19 and other patients, have been caused by approaches restricting fluids, nutrition, antibiotics, effective antivirals, anti-inflammatories, and therapeutic doses of anti-coagulants.

We now see government-dictated medical care at its worst in our history since the **federal government mandated** these ineffective and dangerous treatments for COVID-19, and then *created financial incentives* for hospitals and doctors to use only those “approved” (and paid for) approaches.

Our formerly trusted medical community of hospitals and hospital-employed medical staff has effectively become “bounty hunters” for *your* life. Patients need to now take unprecedented steps to *avoid* going into the hospital for COVID-19.

Patients need to take active steps to plan before getting sick to use early home-based treatment of COVID-19 that can help you *save* your life.

Blessings,

Pastor Bob, [EvanTeachr@aol.com](mailto:EvanTeachr@aol.com)  
[www.pastorbobreid.com](http://www.pastorbobreid.com)  
<http://jesusisthewaythetruththelife.com/node/22>